Dyne completes enrollment of 71 participants in Z-basivarsen DM1 trial expansion

Dyne Therapeutics announced full enrollment in the registrational expansion cohort of its ACHIEVE trial for Z-basivarsen, with topline data expected in Q1 2027 to support potential U.S. Accelerated Approval by Q3 2027. The company targets a potential H1 2028 U.S. launch if FDA grants Priority Review, representing a significant milestone for its myotonic dystrophy Type 1 treatment program.